Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Taylor Capital (NASDAQ: TAYC ) , the holding company of Cole Taylor Bank, a commercial and consumer lending and financial services company located in the Chicago area, skyrocketed as much as 22% after agreeing to be purchased by MB Financial (NASDAQ: MBFI ) .
So what: Under the terms of the deal and as of Friday's closing value, MB Financial is offering $22 per share, close to $680 million, for Taylor Capital. MB Financial plans to finance the deal with a mixture of cash and stock -- $4.08 in cash and 0.64318 shares of MB Financial for each share of Taylor Capital. The acquisition by MB Financial is expected to boost the bank into the top-five market share for Cook County in Illinois and is forecast to be immediately accretive to earnings. MB Financial noted the deal would close sometime in the first half of 2014.
Top Up And Coming Companies To Buy Right Now: Phillips 66 Partners LP (PSXP)
Phillips 66 Partners LP, incorporated on February 20, 2013, owns, operates, develops and acquires primarily fee-based crude oil, refined petroleum product and natural gas liquids (NGL) pipelines and terminals and other transportation and midstream assets. The Company�� initial assets consist of the three systems, which include Clifton Ridge crude system, Sweeny to Pasadena products system and Hartford Connector products system. A refined petroleum product pipeline, terminal and storage system extending from Phillips 66�� Sweeny refinery in Old Ocean, Texas, to its refined petroleum product terminal in Pasadena, Texas, and ultimately connecting to the Explorer and Colonial refined petroleum product pipeline systems and other third-party pipeline and terminal systems.
A crude oil pipeline, terminal and storage system located in Sulphur, Louisiana, that is the primary source for delivery of crude oil to Phillips 66�� Lake Charles refinery. A refined petroleum product pipeline, terminal and storage system located in Hartford, Illinois, that distributes diesel and gasoline produced at the Wood River refinery (a refinery owned by a joint venture between Phillips 66 and Cenovus Energy Inc.) to third-party pipeline and terminal systems, including the Explorer refined petroleum product pipeline system.
Advisors' Opinion:- [By Monica Wolfe]
Phillips 66 Partners LP (PSXP)
Chairman and CEO Greg Garland made a significant buy during the company�� IPO on July 26. Garland purchased 35,000 shares at $23 per share. This transaction cost him a total of $805,000.
- [By Robert Rapier] In last week’s MLP Investing Insider (MLPII) I took a look at the MLP IPOs from the first half of 2013. Today I review the half dozen that have debuted in the second half of 2013.
Phillips 66 Partners (NYSE: PSXP) launched on July 23 as one of the most anticipated IPOs this year. PSXP owns some of the midstream logistics assets of its sponsor, Phillips 66 (NYSE: PSX). PSXP has yet to announce its first distribution, but according to the IPO prospectus the minimum yield will be $0.85 per unit on an annualized basis. At the current unit price, this equates to a minimum annual yield of 2.8 percent, which is mainly a function of the huge run-up in unit price between the IPO pricing and today’s unit price. If the distribution does come in near the minimum, the unit price will almost certainly correct downward following the announcement.
Marlin Midstream Partners (Nasdaq: FISH) launched on July 26. The partnership provides natural gas gathering, transportation, treating and processing services, NGL transportation services and crude oil transloading services. Marlin’s assets include three natural gas processing facilities in Texas, two natural gas gathering systems, two NGL transportation pipelines, and two crude oil transloading facilities. Marlin expects most of the gross margin to be generated under fee-based, minimum volume commercial agreements.
Marlin targets a coverage ratio of 1.10x to support distributions. Marlin’s partnership agreement provides for a minimum quarterly distribution of $0.35 per unit for each whole quarter, or $1.40 per unit on an annualized basis. The prorated distribution for the two months of the recently concluded quarter since tje IPO should be announced soon. The minimum annual yield based on the current unit price is projected at 7.7 percent. The unit price has declined 6 percent since the IPO.
Top 5 Heal Care Companies To Buy For 2014: Pure Energy Minerals Ltd (PE)
Pure Energy Minerals Ltd manufactures biological logical products. Advisors' Opinion:- [By Matt Jarzemsky var popups = dojo.query(".socialByline .popC"); popups.forEach]
Parsley Energy Inc.(PE) opened higher Friday after the Midland, Tex.-based oil driller and some of its early shareholders sold more shares than planned at a higher price than expected in an IPO. The shares jumped 19% in morning trading.
Top 5 Heal Care Companies To Buy For 2014: NeoStem Inc (NBS)
NeoStem, Inc., incorporated on September 18, 1980, operates in cellular therapy industry. Cellular therapy addresses the process by which new cells are introduced into a tissue to prevent or treat disease, or regenerate damaged or aged tissue, and consists of a separate therapeutic technology platform in addition to pharmaceuticals, biologics and medical devices. The Company�� business model includes the development of novel cell therapy products, as well as operating a contract development and manufacturing organization (CDMO) providing services to others in the regenerative medicine industry. Progenitor Cell Therapy, LLC, the Company�� wholly owned subsidiary (PCT), is a CDMO in the cellular therapy industry. PCT has provided pre-clinical and clinical current Good Manufacturing Practice (cGMP) development and manufacturing services to over 100 clients advancing regenerative medicine product candidates through rigorous quality standards all the way through to human testing.
PCT has two cGMP, cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. Its core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services. The Company�� wholly-owned subsidiary, Amorcyte, LLC (Amorcyte) is developing its own cell therapy, AMR-001, for the treatment of cardiovascular disease. AMR-001 represents its clinically advanced therapeutic product candidate and enrollment for its Phase II PreSERVE clinical trial to investigate AMR-001's safety and efficacy in preserving heart function after a heart attack in a particular type of post Acute Myocardial Infarction (AMI) patients.
Through the Company�� subsidiary, Athelos Corporation (Athelos), the Company is collaborating w! ith Becton-Dickinson in early stage clinical development of a therapy utilizing T-cells, collaborating for autoimmune and inflammatory conditions, including but not limited to, graft vs. host disease, type 1 diabetes, steroid resistant asthma, lupus, multiple sclerosis and solid organ transplant rejection. The Company�� pre-clinical assets include its Very Small Embryonic Like (VSEL) Technology platform. The Company has basic research and development capabilities, manufacturing facilities on both the east and west coast of the United States.
Advisors' Opinion:- [By John Udovich]
Small cap ALS and stem cell stock�Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) surged 22.68%�ahead if its Monday ice bucket challenge when they will release the final results from�a phase 2a clinical trial���meaning its worth taking a closer look at the stock along with the performance of stem cell stocks or ALS stocks like Cytokinetics, Inc (NASDAQ: CYTK), Neuralstem, Inc (NYSEMKT: CUR) and NeoStem Inc (NASDAQ: NBS). However, Brainstorm Cell Therapeutics does have a history of being the subject of paid promotions and/or investor relations activities when it was trading on the OTC.
- [By John Udovich]
Summer and the slow news for the market that usually comes with it�is over with and both stem cell researchers or small� cap stem cell stocks like Advanced Cell Technology, Inc (OTCBB: ACTC), Neuralstem, Inc (NYSEMKT: CUR), NeoStem Inc (NASDAQ: NBS), International Stem Cell Corp (OTCMKTS: ISCO)�and BioRestorative Therapies (OTCBB: BRTX) having news for investors and traders alike. Consider the following:
- [By Stock Investor]
Back in April in my article titled, "Regenerative Medicine's Time Has Come", I covered two very interesting companies focused on this field: NeoStem Inc. (NBS) and Neuralstem Inc. (CUR).
- [By Roberto Pedone]
Another under-$10 biopharmaceutical player that's starting to trend within range of triggering a big breakout trade is Neostem (NBS), engages in the development of proprietary cell therapy products. This stock has been hit hard by the sellers during the last three months, with shares off by 22%.
If you take a look at the chart for Neostem, you'll notice that this stock has recently spiked higher back above both its 50-day moving average at $6.41 and its 200-day moving average of $6.60 a share. This move has also pushed shares of NBS back above some near-term overhead resistance levels at $6.57 to $6.98 a share. That move is quickly pushing NBS within range of triggering another breakout trade above some key near-term overhead resistance.
Market players should now look for long-biased trades in NBS if it manages to break out above some near-term overhead resistance at $7.22 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action 327,514 shares. If that breakout triggers soon, then NBS will set up to re-fill some of its previous gap down zone from October that started just above $8 a share. If that that gap gets filled with volume, then NBS could easily tag its next major overhead resistance levels at $9 to $9.50 a share, or even its 52-week high at $9.89 a share.
Traders can look to buy NBS off weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average of $6.41 a share, or near more support at $6 a share. One can also buy NBS off strength once it takes out $7.22 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top 5 Heal Care Companies To Buy For 2014: HTC Corp (2498.TW)
HTC Corporation is principally engaged in the research, development and manufacturing of smart handheld devices. The Company provides touch phones, personal digital assistant (PDA) phones, smart phones, Android smart phones, Windows OS smart phones and panel computers, among others. The Company offers its products under the brand name of HTC, including HTC Butterfly series, Desire series, HTC One series, HTC Sensation series, HTC Explorer series, HTC Rhyme series, as well as HTC Radar series, among others. The Company distributes its products within domestic market and to overseas markets. Advisors' Opinion:- [By Tom Rojas var popups = dojo.query(".socialByline .popC"); popups.forEach(func]
Audio-equipment maker Monster LLC and its chief executive sued Apple Inc.'s(AAPL) Beats Electronics LLC, its co-founders Jimmy Iovine and Dr. Dre, and Taiwanese smartphone maker HTC Corp.(2498.TW) for allegedly conspiring to dupe Monster out of a deal with Beats before the company was sold to Apple for $3.2 billion last year.
No comments:
Post a Comment